STUDY OBJECTIVES: It has been suggested that chronic viral infection may increase the risk for development of COPD. This prospective study was designed to determine that chronic hepatitis C virus (HCV) infection is associated with accelerated decline of lung function in patients with COPD, and that antiviral therapy against HCV is effective for such patients. DESIGN: Prospective 5-year follow-up study. SETTING: University hospital. PATIENTS: Fifty-nine patients with COPD (group A, 15 HCV-negative ex-smokers; group B, 14 HCV-negative current smokers; group C, 14 HCV-positive ex-smokers; group D, 16 HCV-positive current smokers). INTERVENTIONS: After a 5-year follow-up period, 21 HCV-positive patients received interferon (IFN)-alpha therapy. MEASUREMENTS AND RESULTS: The rate of annual decline in FEV(1) and diffusing capacity of the lung for carbon monoxide (DLCO) during the 5-year follow-up period were significantly higher in group B (DeltaFEV(1), 59.7 mL/yr [SD, 17.5], p = 0.0008; DeltaDLCO, 3.50%/yr [SD, 0.44], p < 0.0001) and group C (DeltaFEV(1), 54.0 mL/yr [SD, 15.3], p = 0.0128; DeltaDLCO, 3.36%/yr [SD, 0.28], p < 0.0001) than in group A (DeltaFEV(1), 33.5 mL/yr [SD, 7.7]; DeltaDLCO, 2.66%/yr [SD, 0.34]). Moreover, these parameters in group D (DeltaFEV(1), 79.5 mL/yr [SD, 20.6]; DLCO, 4.5%/yr [SD, 0.40]) were also significantly higher than those in group B and group C. We evaluated the DeltaFEV(1) after IFN therapy during the 3-year follow-up period in the 8 IFN responders and 13 IFN nonresponders. DeltaFEV(1) in the IFN nonresponders did not significantly change during the 3-year follow-up period (before, 65.5 mL/yr [SD, 23.5]; after, 66.1 mL/yr [SD, 24.0]). However, DeltaFEV(1) in the IFN responders significantly decreased (before, 68.4 mL/yr [SD, 26.2]; after, 57.3 mL/yr [SD, 23.6], p = 0.0116). CONCLUSIONS: Our findings suggest that chronic HCV infection might accelerate decline in lung function in patients who already have COPD.
STUDY OBJECTIVES: It has been suggested that chronic viral infection may increase the risk for development of COPD. This prospective study was designed to determine that chronic hepatitis C virus (HCV) infection is associated with accelerated decline of lung function in patients with COPD, and that antiviral therapy against HCV is effective for such patients. DESIGN: Prospective 5-year follow-up study. SETTING: University hospital. PATIENTS: Fifty-nine patients with COPD (group A, 15 HCV-negative ex-smokers; group B, 14 HCV-negative current smokers; group C, 14 HCV-positive ex-smokers; group D, 16 HCV-positive current smokers). INTERVENTIONS: After a 5-year follow-up period, 21 HCV-positive patients received interferon (IFN)-alpha therapy. MEASUREMENTS AND RESULTS: The rate of annual decline in FEV(1) and diffusing capacity of the lung for carbon monoxide (DLCO) during the 5-year follow-up period were significantly higher in group B (DeltaFEV(1), 59.7 mL/yr [SD, 17.5], p = 0.0008; DeltaDLCO, 3.50%/yr [SD, 0.44], p < 0.0001) and group C (DeltaFEV(1), 54.0 mL/yr [SD, 15.3], p = 0.0128; DeltaDLCO, 3.36%/yr [SD, 0.28], p < 0.0001) than in group A (DeltaFEV(1), 33.5 mL/yr [SD, 7.7]; DeltaDLCO, 2.66%/yr [SD, 0.34]). Moreover, these parameters in group D (DeltaFEV(1), 79.5 mL/yr [SD, 20.6]; DLCO, 4.5%/yr [SD, 0.40]) were also significantly higher than those in group B and group C. We evaluated the DeltaFEV(1) after IFN therapy during the 3-year follow-up period in the 8 IFN responders and 13 IFN nonresponders. DeltaFEV(1) in the IFN nonresponders did not significantly change during the 3-year follow-up period (before, 65.5 mL/yr [SD, 23.5]; after, 66.1 mL/yr [SD, 24.0]). However, DeltaFEV(1) in the IFN responders significantly decreased (before, 68.4 mL/yr [SD, 26.2]; after, 57.3 mL/yr [SD, 23.6], p = 0.0116). CONCLUSIONS: Our findings suggest that chronic HCV infection might accelerate decline in lung function in patients who already have COPD.
Authors: Matthew R Gingo; Mehdi Nouraie; Cathy J Kessinger; Ruth M Greenblatt; Laurence Huang; Eric C Kleerup; Lawrence Kingsley; Deborah K McMahon; Alison Morris Journal: Ann Am Thorac Soc Date: 2018-02
Authors: Siddharth A Mahure; Joseph A Bosco; James D Slover; Jonathan Vigdorchik; Richard Iorio; Ran Schwarzkopf Journal: Clin Orthop Relat Res Date: 2018-02 Impact factor: 4.176
Authors: M Bradley Drummond; Gregory D Kirk; Jacquie Astemborski; Mariah M Marshall; Shruti H Mehta; John F McDyer; Robert H Brown; Robert A Wise; Christian A Merlo Journal: Thorax Date: 2011-11-16 Impact factor: 9.139
Authors: William A Fischer; Michael B Drummond; Christian A Merlo; David L Thomas; Robert Brown; Shruti H Mehta; Robert A Wise; Greg D Kirk Journal: COPD Date: 2013-07-17 Impact factor: 2.409
Authors: Luis García-Olmos; Angel Alberquilla; Victoria Ayala; Pilar García-Sagredo; Leticia Morales; Montserrat Carmona; María José de Tena-Dávila; Mario Pascual; Adolfo Muñoz; Carlos H Salvador; Jose L Monteagudo Journal: BMC Fam Pract Date: 2013-01-16 Impact factor: 2.497